CN113395978A - 与靶向CTLA-4的工程化Fc-抗原结合结构域构建体有关的组合物和方法 - Google Patents

与靶向CTLA-4的工程化Fc-抗原结合结构域构建体有关的组合物和方法 Download PDF

Info

Publication number
CN113395978A
CN113395978A CN201980059449.6A CN201980059449A CN113395978A CN 113395978 A CN113395978 A CN 113395978A CN 201980059449 A CN201980059449 A CN 201980059449A CN 113395978 A CN113395978 A CN 113395978A
Authority
CN
China
Prior art keywords
domain
polypeptide
monomer
domain monomer
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980059449.6A
Other languages
English (en)
Chinese (zh)
Inventor
A·曼宁
J·C·兰辛
D·奥尔蒂斯
L·鲁蒂茨基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Momenta Pharmaceuticals Inc
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of CN113395978A publication Critical patent/CN113395978A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201980059449.6A 2018-07-11 2019-07-11 与靶向CTLA-4的工程化Fc-抗原结合结构域构建体有关的组合物和方法 Pending CN113395978A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862696754P 2018-07-11 2018-07-11
US62/696754 2018-07-11
US201862743976P 2018-10-10 2018-10-10
US62/743976 2018-10-10
PCT/US2019/041293 WO2020014413A2 (en) 2018-07-11 2019-07-11 Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ctla-4

Publications (1)

Publication Number Publication Date
CN113395978A true CN113395978A (zh) 2021-09-14

Family

ID=69141692

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980059449.6A Pending CN113395978A (zh) 2018-07-11 2019-07-11 与靶向CTLA-4的工程化Fc-抗原结合结构域构建体有关的组合物和方法

Country Status (11)

Country Link
US (1) US20220064298A1 (https=)
EP (1) EP3820521A4 (https=)
JP (1) JP2021532085A (https=)
KR (1) KR20210044783A (https=)
CN (1) CN113395978A (https=)
AU (1) AU2019301160A1 (https=)
BR (1) BR112021000427A2 (https=)
CA (1) CA3106207A1 (https=)
IL (1) IL280014A (https=)
MX (1) MX2021000306A (https=)
WO (1) WO2020014413A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024212152A1 (en) * 2023-04-13 2024-10-17 Adagene Pte. Ltd. Anti-ctla4 antibodies and methods of making and using the same

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109517059B (zh) 2011-06-30 2023-03-28 中外制药株式会社 异源二聚化多肽
WO2022034920A1 (en) * 2020-08-14 2022-02-17 Chugai Seiyaku Kabushiki Kaisha One-armed antigen-binding molecules and uses thereof
AU2022212978A1 (en) * 2021-01-28 2023-08-31 The Hospital For Sick Children Multabody constructs, compositions, and methods
TWI864408B (zh) * 2021-06-25 2024-12-01 日商中外製藥股份有限公司 抗ctla-4抗體的用途
US12448451B2 (en) 2021-06-25 2025-10-21 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
EP4731655A1 (en) * 2023-06-23 2026-04-29 CureVac SE Nucleic acid encoded antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140242077A1 (en) * 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
CN106913869A (zh) * 2017-03-17 2017-07-04 信达生物制药(苏州)有限公司 一种抗ctla‑4单克隆抗体制剂及其应用
WO2017151971A2 (en) * 2016-03-02 2017-09-08 Momenta Pharmaceuticals, Inc. METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
WO2017205434A1 (en) * 2016-05-23 2017-11-30 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR075989A1 (es) * 2009-04-10 2011-05-11 Lilly Co Eli Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
CA2994746A1 (en) * 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
WO2018035710A1 (en) * 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
JP6976322B2 (ja) * 2016-10-10 2021-12-08 クラウン バイオサイエンス，インコーポレイテッド（タイツァン） 新規抗ｃｔｌａ４抗体
WO2018089829A1 (en) * 2016-11-10 2018-05-17 Fortis Therapeutics, Inc. Cd46-specific effector cells and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140242077A1 (en) * 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
WO2017151971A2 (en) * 2016-03-02 2017-09-08 Momenta Pharmaceuticals, Inc. METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
WO2017205434A1 (en) * 2016-05-23 2017-11-30 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
CN106913869A (zh) * 2017-03-17 2017-07-04 信达生物制药(苏州)有限公司 一种抗ctla‑4单克隆抗体制剂及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MENGNAN HE等: "Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies", 《ONCOTARGET》, vol. 8, no. 40, pages 67129 - 67139, XP055412741, DOI: 10.18632/oncotarget.18004 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024212152A1 (en) * 2023-04-13 2024-10-17 Adagene Pte. Ltd. Anti-ctla4 antibodies and methods of making and using the same

Also Published As

Publication number Publication date
MX2021000306A (es) 2021-09-08
EP3820521A2 (en) 2021-05-19
CA3106207A1 (en) 2020-01-16
AU2019301160A1 (en) 2021-02-25
IL280014A (en) 2021-03-01
US20220064298A1 (en) 2022-03-03
WO2020014413A3 (en) 2020-02-20
BR112021000427A2 (pt) 2021-04-06
WO2020014413A2 (en) 2020-01-16
JP2021532085A (ja) 2021-11-25
KR20210044783A (ko) 2021-04-23
EP3820521A4 (en) 2022-04-13

Similar Documents

Publication Publication Date Title
CN113395978A (zh) 与靶向CTLA-4的工程化Fc-抗原结合结构域构建体有关的组合物和方法
JP2020514301A (ja) 改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法
US20220267460A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
CN113194990A (zh) 与靶向CD38的工程化Fc-抗原结合结构域构建体有关的组合物和方法
CN113164590A (zh) 与靶向CCR4的工程化Fc-抗原结合结构域构建体有关的组合物和方法
CN112996910A (zh) 与靶向PD-L1的工程化Fc-抗原结合结构域构建体有关的组合物和方法
CN113382749A (zh) 与工程化Fc-抗原结合结构域构建体有关的组合物和方法
US20210284717A1 (en) Compositions and methods related to engineered fc-antigen binding domain constructs
CN113164592A (zh) 与工程化Fc-抗原结合结构域构建体有关的组合物和方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210914

WD01 Invention patent application deemed withdrawn after publication